GSK Augmentin ES Conversion Rate Reaches 31%; XR Filing Imminent
Executive Summary
GlaxoSmithKline is converting about one-third of Augmentin suspension Rxs to the ES-600 formulation, GSK Chief Operating Officer Bob Ingram told securities analysts Feb. 14
You may also be interested in...
FDA Patent Listing Review System Suggested By Paxil Appeals Court
An FDA system for review of patents for "Orange Book" listing would be feasible, U.S. Federal Circuit Judge Jay Plager suggested Feb. 4
FDA Patent Listing Review System Suggested By Paxil Appeals Court
An FDA system for review of patents for "Orange Book" listing would be feasible, U.S. Federal Circuit Judge Jay Plager suggested Feb. 4
Generic Success In Patent Cases May Slow Momentum For Waxman/Hatch Fix
A string of recent patent victories for the generic industry may take some momentum away from the drive for Waxman/Hatch reform